抗TIF1-γ抗体阳性皮肌炎中细胞因子/趋化因子谱的差异聚类
该研究对27例抗TIF1-γ抗体阳性DM/CADM患者检测24种细胞因子/趋化因子,通过主成分分析和无监督聚类识别出两个亚群。聚类2表现为更高皮肤活动度、肌无力、抗TIF1-γ抗体水平及恶性肿瘤率,且CXCL10、CCL2、galectin-9、IL-18、TNF-α水平更高。细胞因子/趋化因子谱可区分不同疾病模式、器官受累和临床结局的患者亚群。
要点
- 抗TIF1-γ阳性DM/CADM可分为「皮肤为主」和「高炎症」两个细胞因子聚类。
- 高炎症聚类患者恶性肿瘤率(73.3% vs 25.0%)、肌无力及抗体水平更高。
- 高炎症聚类皮肤活动度更高,CXCL10、CCL2、galectin-9等炎症因子水平更高。
核心结论
- 在抗TIF1-γ抗体阳性DM/CADM中,基于细胞因子/趋化因子谱可识别出「皮肤为主」和「高炎症」两个聚类,对应不同疾病模式、器官受累和临床结局。
研究设计与样本
- 研究纳入27例抗TIF1-γ抗体阳性DM/CADM患者,采用Luminex 200系统检测血清24种细胞因子/趋化因子水平。
- 采用主成分分析和无监督层次聚类降维并建立患者亚组,用Spearman相关系数分析细胞因子/趋化因子与疾病活动标志物的相关性。
主要发现
- 聚类1中CADM诊断比例高于聚类2(58.3% vs 6.7%,P=0.008)。
- 聚类2皮肤疾病活动度评分(Cutaneous DM Disease Area and Severity Index-Activity)高于聚类1[38.6(10.4) vs 25.3(10.0),P=0.003]。
- 聚类2中肌无力(Medical Research Council量表≤3)比例高于聚类1(33.3% vs 0.0%,P=0.047),抗TIF1-γ抗体水平更高[92.4(20.6) vs 66.9(13.9),P=0.001]。
- 聚类2恶性肿瘤发生率高于聚类1(73.3% vs 25.0%,P=0.021)。
- 聚类2血清CXCL10[564.2(258.8) vs 122.0(97.8),P<0.001]、CCL2[1136.6(545.4) vs 441.6(163.3),P<0.001]、galectin-9[38879.6(20009.3) vs 12612.4(6640.0),P<0.001]、IL-18[436.1(188.9) vs 243.0(114.5),P=0.003]、TNF-α[9.3(3.8) vs 5.6(2.4),P=0.007]水平高于聚类1,TNFRI水平低于聚类1[1385.1(338.2) vs 2605.6(928.5),P<0.001]。
临床怎么用
- 对初诊抗TIF1-γ抗体阳性DM/CADM患者,可考虑检测CXCL10、CCL2、galectin-9、IL-18、TNF-α等细胞因子/趋化因子谱以辅助风险分层。
- 若患者呈现高炎症细胞因子聚类特征,应警惕更高的皮肤活动度、肌无力和恶性肿瘤风险,加强相应筛查与随访。
局限性
- 研究样本量较小(27例),聚类结果需在更大规模队列中验证。
- 原文未报告细胞因子/趋化因子谱检测的标准化方法、重复性及成本效益信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: DM and clinically amyopathic DM (CADM) patients with positive expression of anti-transcription intermediary factor 1-γ (anti-TIF1-γ) antibody (Ab) are characterized by distinct clinicopathological features. We aimed to determine the role of cytokine/chemokine profiles in the classification of anti-TIF1-γ positive DM/CADM patients. METHODS: Serum levels of 24 cytokines/chemokines were measured in 27 anti-TIF1-γ positive DM/CADM patients by a Luminex 200 system. Principal components analysis and unsupervised hierarchical clustering were used to reduce variables and establish patient subgroups. Spearman's correlation coefficient was calculated between cytokine/chemokine levels and disease activity markers. RESULTS: Among anti-TIF1-γ positive DM/CADM patients, two distinct patient clusters were identified. The diagnosis of CADM was more common in cluster 1 than in cluster 2 (58.3% vs 6.7%, P = 0.008). Skin disease activity was higher in cluster 2 than in cluster 1 as measured by Cutaneous DM Disease Area and Severity Index-Activity [38.6 (10.4) vs 25.3 (10.0), P = 0.003]. Patients within cluster 2 exhibited significant muscle weakness (Medical Research Council scale ≤ 3, 33.3% vs 0.0%, P = 0.047), higher levels of anti-TIF1-γ Ab [92.4 (20.6) vs 66.9 (13.9), P = 0.001] and an increased malignancy rate (73.3% vs 25.0%, P = 0.021). Cluster 2 exhibited higher serum levels of CXCL10 [564.2 (258.8) vs 122.0 (97.8), P < 0.001], CCL2 [1136.6 (545.4) vs 441.6 (163.3), P < 0.001], galectin-9 [38879.6 (20009.3) vs 12612.4 (6640.0), P < 0.001], IL-18 [436.1 (188.9) vs 243.0 (114.5), P = 0.003], TNF-α [9.3 (3.8) vs 5.6 (2.4), P = 0.007] and TNFRI [1385.1 (338.2) vs 2605.6 (928.5), P < 0.001] than cluster 1. CONCLUSION: In anti-TIF1-γ positive DM/CADM, we identified a 'skin-predominant' cluster and a 'hyperinflammation' cluster based on the cytokine/chemokine profiles.Cytokine/chemokine profiles in anti-TIF1-γ positive DM/CADM can identify discrete clusters of patients with different disease patterns, organ involvements and clinical outcomes.
引用
- Zhao Q, Chen Y, Diao L, et al. Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-γ antibody. Rheumatology (Oxford). 2022. PMID: 34508564. doi:10.1093/rheumatology/keab625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。